RNK288

RNK288 is a preclinical-stage small interfering RNA (siRNA) therapeutic being developed by Shanghai Rona Therapeutics for the treatment of IgA Nephropathy (IgAN). The drug is developed using the company's proprietary GAIA platform, which utilizes GalNAc-conjugation technology to achieve targeted delivery to the liver. While the specific molecular target of RNK288 remains undisclosed, the therapy is designed to silence genes involved in the underlying pathology of IgAN, a chronic kidney disease characterized by the accumulation of immunoglobulin A (IgA) deposits in the kidneys. By leveraging the RNA interference (RNAi) mechanism, RNK288 aims to provide a highly specific and potentially long-acting treatment option for patients with this progressive renal condition.